Dr. Reardon on Updated Data From the Phase II ReACT Trial
David Reardon, MD, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma.
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma. Reardon presented these data at the 2015 Annual Meeting of the Society for Neuro-Oncology (SNO).
At the 2015 ASCO Annual Meeting, Reardon and his colleagues reported a survival benefit with the combination, though the data were not fully mature.
Reardon says that at the SNO meeting, he is reporting data that show that the survival benefit is increased and enhanced. In fact, the 2-year survival rate in the trial was 25% with rindopepimut compared with 0% for patients treated in the control arm.
<<<
